Project Details
| Short title | MorningLyte |
|---|---|
| Status | Active |
| Effective start/end date | 02.06.2025 → 31.05.2029 |
Fields of science
- 302024 Haematology
- 302055 Oncology
Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti- CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma (MorningLyte)
- Schmitt, Clemens (PI)
- Krivic, Denis (Researcher)
- Lichtenauer, Nina (Researcher)
- Kühr, Thomas (Researcher)
- Schneeweiß, Bruno (Researcher)
- Piringer, Gudrun (Researcher)
- Popp, Henning Detlef (Researcher)
- Krenosz, K. J. (Researcher)
- Ghanem, Riad (Researcher)
- Stefan, Alex (Researcher)
- Schwarz, Heike Kathleen (Researcher)
- Kovacsova, Judita (Researcher)
- Kausche, Lea Elisabeth (Researcher)
- Stegemann, Maike (Researcher)
- Klein, Katharina (Researcher)
- Trathnigg, Nicolas (Researcher)
Project: Clinical studies › Clinical Study (Industry project)